Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome

Chronic benign lymphoproliferation and autoimmune cytopenias are the main features requiring treatment in FAS mutant patients with autoimmune lymphoproliferative syndrome (ALPS).[1][1],[2][2] Successful use of the mTOR inhibitor rapamycin was initially reported in the treatment of refractory